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Abstract
Down syndrome (DS) or trisomy 21 is one of the most important genetic causes of
mental retardation. Sincere and significant attempts have been made towards
understanding the congenital diseases that affect DS patients. Better understanding
of gene networks associated with such malformations will help to predict the complex
genetic trait behind congenital disease in DS and will also provide the basis for tailored
gene therapies that could begin to heal or prevent such malformation without the need
to resort to invasive surgery. Further, susceptible mutation screening in women will
also be helpful for both prenatal diagnosis of DS birth and assessing the risk of
predisposition to Alzheimer’s disease and congenital heart disease. Stress condition
and neurodegeneration are two important markers in Down syndrome patients and
mtDNA variation can also be used as an important biomarker. It has been suggested
that nutraceuticals which reduce reactive oxygen species (ROS) level may be used to
treat trisomy 21 condition. As mitochondria play a crucial role in the regulation of free
radicals, only a detail analysis will reveal the origin of phenotypic characteristics
among trisomy 21 DS patients. On the other hand, several mechanisms are responsible
for neurodegeneration as well as altered cognition. It includes impaired neurogenesis
leading to hypocellularity in the cortex, hippocampus and cerebellum, altered
dendritic morphology, altered synapses, increased inhibition and neurodegeneration.
The new knowledge of the pathogenic mechanisms in DS individuals has been
acquired from mouse model. These studies provide the basis for developing new
drugs for clinical trials in DS individuals and to sustain the hope that some of these
drugs will be useful in treating intellectual disability in DS individuals.
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1. Introduction
Down syndrome (DS) or trisomy 21 is the most frequent live born chromosomal aneuploidy
in humans characterized by an extra chromosome 21 [1]. Myriad researches have contributed
significantly towards understanding the management and control of disorders associated with
Down syndrome. Since middle of 19th century, Down syndrome research has progressed
alongside and in response to more general scientific advances. These researches attempt to
cover the etiology, treatment, management, control, and prevention of DS. Both in vitro and
in vivo experiments are carried out to understand the molecular mechanism of the origin of
this aneuploidy. Many exciting areas are currently being investigated in relation to DS. A
number of genes have been identified, which are putative candidates for phenotypic abnor‐
malities. Use of Down syndrome mouse model, which is segmental trisomies of homologous
segment of human chromosome 21, has facilitated greatly the process of reverse genetic
approach to explore the gene–protein relationship in Down syndrome. Extensive studies are
carried out in areas involving psycho-somatic and neural control of functions such as learning,
behavior, and foetal brain development.
The research on Down syndrome has progressed and it can be assumed that people with Down
syndrome will enjoy better quality of life in future. The most prevalent disorders among Down
syndrome patients that have attracted the attention of research community are Alzheimer’s
disease and congenital heart defect. To go deep into the problem and to understand the exact
etiology of these disorders, several approaches have been taken. One among them is mouse
models for segmental trisomies, which are being used for better understanding of these disease
conditions. The ultimate goal of all research approaches is to contribute toward the better
management of lifestyle of Down syndrome individuals.
2. Congenital Heart Disease (CHD) in Down Syndrome
Down Syndrome (DS) is characterized by a combination of multifaceted congenital abnor‐
malities with various degrees of severity. Among them cardiac anomalies are found in nearly
50% of DS cases.Cardiac abnormalities in DS include mainly atrioventricular septal defect
(AVSD), ventricular septal defects (VSD), atrial septal defect(ASD) and few percentages of
isolated tetralogy of fallot (TOF) of which approximately 40–60% includes an atrioventricular
septal defect (AVSD) [2]. The developmental basis of atrioventricular septal defect also known
as an atrioventricular canal defect or endocardial cushion defect is complex. This congenital
cardiac anomaly occurs when the superior and inferior endocardial cushions fail to close
completely, resulting in incomplete formation of atrial and ventricular valves and septa.. The
tricuspid and mitral valves that normally separate the hearts upper and lower chambers are
not formed as individual valves; instead, a single large valve is formed which does not close
tightly. A large hole in the centre of the heart exists where the wall between the upper chambers
join the wall between the lower chambers, allowing the blood to flow between all the chambers
of the heart..This is called as a complete AVSD. In case of partial AVSD, there is usually a hole
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in the wall between the atria or a hole in the wall between the ventricles near the middle of the
heart, but there are usually two valves between the atria and ventricles and not a common
valve as seen in complete AVSD. In partial AVSD, usually the mitral valve does not close
completely and allows the blood to leak backward.
2.1. Recent studies on CHD
Higher incidence of congenital heart disease (CHD), especially AVSD, associated with DS has
made the identification of CHD associated genes very challenging. Therefore, many researches
focused on chromosome 21 (Ch21) genes, based on the hypothesis that overexpression of these
genes may play a role in the etiology of AVSD in DS. Studies have implicated Ch21 genes,
COL6A1, COL6A2, and DSCAM as potential contributors to heart defects in DS [3–5]. A recent
study has shown that overexpression of DSCAM and COL6A2 cooperatively causes atrial
defects in mice [6]. Recently a candidate gene approach carried out among Down syndrome
individuals with AVSD and Down syndrome without CHD suggests a potential contribution
of VEGF-A, ciliome, hedgehog and folate pathway genes such as MTHFR, MTRR, SLC19A1,
MTR, and CBS to the pathogenesis of CHD in DS [7–9].
Many studies based on the premise that myriad of genes are involved in cardiogenesis, and
perturbation in any of this gene by mutation can cause CHD, therefore, highlighting the role
of non-chromosome 21 gene mutation to play a key role in the etiology of AVSD in DS. For
example, pathogenic mutations in the CRELD1 gene have been found to be associated with
AVSD [10]. Studies have also shown that how polymorphic haplotypes of CRELD1 increase
the risk of AVSD, and the susceptibility is exacerbated in DS, possibly due to the trisomy 21
genetic background [11]. Furthermore, there is a growing body of evidence, highlighting the
role of epigenetic in the development of AVSD in DS [12].
There are multiple risk alleles that play an important role in the pathogenesis of congenital
heart disease (CHD) in DS. Alone trisomy 21 background is not enough to reach the threshold
needed for the development of CHD. There exists a multifactorial model where genetic and
epigenetic variants, unknown environmental factors, and stochastic events are required in
addition to trisomy 21 background to cross the threshold for developing CHD in DS.
3. Relationship between Alzheimer’s Disease and Down Syndrome
Alzheimer’s disease (AD) is well known as the major cause of dementia in elderly people,
characterized mainly by cognitive decline and other motor dysfunction. Several lines of
researches indicate that Alzheimer’s disease share some common genetic factors with Down
syndrome. Imaging techniques have confirmed AD-like pathogenic signs in the brain of most
DS patients after 40 years of age [13, 14]. Frequent birth of babies with DS is evident in families
with AD patients. Moreover, greater number of AD patients are counted among the relatives
of DS. Neurons progressively and irreversibly die chiefly due to deposition of amyloid beta
protein and eventually perturb neurosynaptic circuits in the brain [15]. The amyloid hypothesis
states that APP (amyloid precursor protein) gene, located on chromosome 21, encodes for
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amyloid precursor protein which is proteolyzed by enzymatic cascade and eventually produce
amyloid beta protein that in turn oligomerizes and forms beta-plaque [16]. The increased
amyloid load due to overexpression of APP in trisomy 21 cells is hypothesized to be a cause
of AD in DS [17]. Moreover, APP gene mutations are also found in both AD and DS [18].
Apolipoprotein E (APOE) is one of the key genes involved in the manifestation in sporadic
AD cases; epsilon 4 allele of this gene is reported to be associated with deterioration in cognitive
ability in DS patients [19].
3.1. Theory of chromosomal missegregation
Scientists have pointed out that chromosomal segregation error may be the possible underly‐
ing molecular link between these two disorders [20, 21]. Abnormality in cell cycle regulation
due to mutations in different genes involved in both sporadic and familial AD cases is also
apparent [20, 22, 23]. According to this theory, AD patients bear mosaic aneuploid cells in
central and peripheral nervous system which are susceptible to apoptosis [20]. Besides neurons
and buccal cells, lymphocytes are also found to be trisomic for chromosome 21 [23–27]. Again,
inflammatory responses induced by overexpression of IL-1 in trisomic microglia increase
amyloid beta production [28].
3.2. Relationship between Alzheimer’s Disease and mothers of Down Syndrome child
Researches revealed that women giving birth to Down syndrome (DS) babies at younger age
are prone to have AD with aging [29]. Young mothers bearing DS offspring are also found to
possess APOE epsilon 4 allele with a higher frequency [30]. Presenilin 1(PSEN-1) is another
important gene playing a role in AD pathogenesis. Trisomy 21 aneuploidy and chromosomal
instability are evident in AD patients with mutation in PSEN-1 gene [20, 31]. Association of
polymorphism of PSEN-1 gene (rs165932) is also established in young mother, giving birth to
DS babies due to nondisjunction error in second meiotic division of oocyte [32]. It is postulated
that accumulation of mosaic trisomy 21 cells in both somatic and germline tissue make those
women prone to AD in their later life and also responsible for giving birth to DS child. Thus
the theory of chromosomal missegregation offers us a new insight into the understanding the
molecular mechanism that bridges Down syndrome with Alzheimer’s disease.
3.3. Other common factors linking Alzheimer’s Disease and Down Syndrome
3.3.1. Mitochondrial dysfunction
Mitochondrial dysfunction is associated with AD pathology [33]. Protein members of mito‐
chondrial electron transport chain are found malfunctioning in Alzheimer’s disease [34].
Diminished cytochrome oxidase activity reflecting improper functioning of mitochondria in
AD patients is revealed by biochemical, histochemical, and immune-histochemical analysis
[35]. Showing similarity with AD cases, dysregulation in mitochondria is evident in Down
syndrome etiology [36]. Individuals with DS also exhibit reduced activity of several mito‐
chondrial enzymes, including cytochrome oxidase [37]. Thus oxidative stress due to mito‐
chondrial dysfunction is typical in both AD and DS.
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3.3.2. Abnormal tau phosphorylation
Another very strong hallmark of AD is the presence of intra-neuronal neurofibrillary tangle
made up of hyperphosphorylated tau protein. The neurotoxic effect of these tangles makes the
neurons vulnerable to death. Researchers revealed that the abnormality in tau phosphorylation
is seen both in AD and DS [38]. A kinase enzyme called “dual-specificity tyrosine phosphory‐
lated and regulated kinase 1A” or DYRK1A phosphorylates tau protein. This gene is mapped
in the Down syndrome critical region of chromosome 21, hence present in triple copies in DS
patients, giving rise to enhanced production of DYRK1A [39]. Moreover, hippocampal,
neocortical, and entorhinal-cortical neurons show increased DYRK1A immune-reactivity in
both AD and DS patients [40].
3.3.3. Altered endocytic pathway activity
Altered endocytic pathway activity is another common phenomenon that bridges both
disorders [41]. Neurons internalize and modify extracellular molecules from cell surface via
endocytosis and relay signals for intracellular biosynthetic pathways to occur. Initial process‐
ing of APP and APOE proteins and cellular uptake of amyloid beta take place in the early
endosomes. Bigger size of early endosomes was seen in AD brain, suggesting increased
endocytic pathway activity [42, 43]. Several growth factors, cell surface receptors, and other
plasma proteins can be erroneously degraded and processed by activated early endosome in
neurons, exposing them in peril. Such improper endolysis of neuronal glucose transporter is
found responsible in reduced uptake of glucose in AD brain [44, 45]. Strikingly, pyramidal
neurons with enlarged early endosomes are also found in DS fetus at 28 weeks of gestation [41].
4. Mitochondrial DNA analysis in Down Syndrome patients
The double-stranded circular mammalian mtDNA molecule of 16.5 kb contains a single long
noncoding region, a displacement loop (D loop) region, the promoters for transcription of both
mtDNA strands and the origin of leading strand replication (OH). The origin of lagging strand
replication (OL) is surrounded in a cluster of tRNA genes. mtDNA codes two rRNAs (12S and
16S rRNA), 13 mRNAs (ND1–6, ND4L, Cyt b, COI–III, ATP6, and ATP8), and 22 tRNAs (F, V,
L1, I, M, W, D, K, G, R, H, S1, L2, T, P, E, S2, Y, C, N, A, and Q).
4.1. Why study mitochondria in Down Syndrome patients?
Mitochondria controls one of the most important biochemical pathways, oxidative phosphor‐
ylation (OXPHOS). A mild imbalance in mitochondrial function or a slight change in mito‐
chondrial structural integrity might lead to a severe cellular oxidative damage and finally
apoptosis. As Down syndrome is an AD-like disease condition, oxidative stress plays a key
role in disease pathogenesis with inevitable involvement of mitochondria.
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4.2. Structural and biochemical anomalies in mitochondria among Down Syndrome patients
Several mitochondrial anomalies have been reported in trisomy 21 patients over the years of
research. Decreased levels of several mitochondrial enzymes such as monoamine oxidase,
cytochrome oxidase, and isocitrate dehydrogenase have been observed in trisomy 21 patients
[37]. At genetic level, downregulation of mitochondrial enzyme genes and upregulation of
mitochondrial extracellular matrix protein genes have been found out by oligonucleotide
microarray in Down syndrome fetus [46]. The level of another important enzyme, pyruvate
dehydrogenase, is found to decrease in the brain of trisomy 16 mouse [47–49]. At structural
level, heavy accumulation of microfilaments, tubules, and abnormally shaped mitochondria
is reported in cerebellar neuron of trisomy 16 mice [50]. The 20 kD complex has also been found
out to be downregulated [49]. Mitochondrial membrane potential in peripheral blood mono‐
nuclear cell (PBMC) is decreased among Down syndrome individuals, which indicates severe
impairment of mitochondrial function [51].
4.3. mtDNA variations among Down Syndrome patients
mtDNA because of its close proximity to mitochondrial membrane might undergo severe
changes due to reactive oxygen species (ROS). mtDNA contains hyper variable D-loop region
(HDR) and semi-variable regulatory control region (RCR). This particular region is responsible
for overall mtDNA transcription mechanism and any adverse change in this region hampers
the overall transcriptional procedure. Several heteroplasmic mutations have been observed in
Down syndrome brains which include G70A, C114T, C150T, G185A, and 309.1-3insC. Down
syndrome lymphoblasts and control lymphoblast share the A73G variant while they more
commonly have the 309.1inC, A357G, and 522–523delCA [52].
5. Mouse model
In recent years, mouse models are used as standard tool for in vivo study. It provides an insight
into the normal functions and regulation of genes and how these are altered in disease and
how they contribute to severity of this disease. Administration of certain drugs as well as
information on drug action, efficacy, and side effects also can be evaluated by this animal
model [53]. So mouse models are used to enhance our knowledge on human genes, their
functions, interactions, and biochemistry. The most studied mouse model for DS is the Ts65Dn
mouse which possesses an extra copy of the chromosome number 16. The distal segment of
mouse chromosome 16 (MMU16) is homologous to nearly the entire long arm of human
chromosome 21 (HSA21), and thus trisomic mouse models are developed in such a way that
it genetically resembles human condition. Ts65Dn and Ts1Cje mice mimic many of the
behavioral, learning, and developmental deficits characteristics in DS individuals [54–58]. The
availability of sophisticated tools for mouse genetics and the conserved synteny between
MMU16 and HSA21 have provided the basis for the development of many mouse models of
DS. This similarity allows to test the critical region concept and to perform a genetic dissection
of the complex DS phenotype.. The knowledge obtained from these models about the neuro‐
Health Problems in Down Syndrome92
biology of DS have yielded the development and analysis of several therapeutic strategies that
could potentially be used to attenuate cognitive impairments in DS individuals. s
5.1. Recent studies on mouse model
Mouse modeling is a very useful technique to understand the neural mechanism underlying
the cognitive impairment seen in Down syndrome. The association of Alzheimer’s disease with
Down syndrome and the regulation of involved genes are being investigated via mouse model
[59]. DS individuals typically display an average Intelligence Quotient (IQ) of 50 (ranging from
30 to 70) and show an array of altered cognitive and behavioral phenotypes, including the
incomplete and delayed acquisition of motor, linguistic, and visual-spatial abilities, impair‐
ments in learning and memory, and neurobehavioral disorders [60–62]. Holtzman et al. (1996)
suggest that Ts65Dn mice are the most useful animal model to study the developmental and
degenerative abnormalities in the DS brain in vivo [56]. Studies show that Ts65Dn mice mimic
the specific age-related decrease in cholinergic function seen in Down syndrome and Alz‐
heimer’s disease [63]. The degeneration of cholinergic neurons in basal forebrain is age related
and this finding raises the possibility that this model may be used further to understand
mechanisms underlying selective neuronal vulnerability seen in DS and AD. Ts65Dn mice also
carry a trisomy of MMU17 containing 60 genes nonhomologous to Hsa21, so this model does
not have perfect construct validity [64]. Mouse modeling also revealed that the nerve growth
factor (NGF) is required for the normal differentiation of basal forebrain cholinergic neurons
(BFCNs) and the abnormalities in NGF levels or signaling in Ts65Dn mice may determine the
regulating factors in neuronal degeneration [64]. GABA (gamma amino butyric acid) is an
important neurotransmitter that regulates neuronal proliferation, migration, differentiation,
and integration of newly generated neurons [65]. It has been suggested that upregulation of
presynaptic GABA may be responsible for the increased hippocampal inhibitory postsynaptic
potentials (IPSPs) observed in these mice [66]. Netzer et al. have tested the effect of β-amyloid
reductions in the Ts65Dn mice which altered its phenotypes [67]. They administered the
gamma secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester) into mice and this treatment reduced β-amyloid levels and rescued spatial learning
in these mice. β-amyloid is a regulator of the glutamatergic system, and the authors proposed
that the cognitive enhancing effects of DAPT could be mediated by an enhancement and/or a
regulation of excitatory synaptic transmission. It has been proposed that pharmacological
enhancements of the cholinergic system help to diminish the cognitive deterioration in DS with
AD. Another research revealed that an acetylcholinesterase inhibitor, Donepezil, is widely
prescribed to enhance cholinergic transmission to treat DS with dementia. However, the
chronic administration of Donepezil did not improve learning and memory in Ts65Dn mice
and causes ambiguous results in young adult individuals with DS [68]. Another drug named
piracetam shows cognitive-enhancing effects in patients with a number of cognitive disorders
and dementia and also in mouse models though the mechanisms underlying these effects are
unknown [69]. However, piracetam treatment did not improve cognitive impairments in
children with DS or in the Ts65Dn mouse [70].
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The first partial trisomic models, the Ts65Dn and Ts1Cje models, demonstrated that DS
phenotypes could be recapitulated in mice. More recently, knock-out and transgenic mice are
developed in different laboratories for particular genes, though there is no mouse model that
perfectly mimics a human condition. In the last 20 years, mouse models, particularly the
Ts65Dn mouse, have been widely used to understand the neurobiological basis of intellectual
disability.
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